2023 年度监事会工作报告 奥佳华智能健康科技集团股份有限公司（以下简称"公司"）监事会全体成 员根据《中华人民共和国公司法》及公司章程等法律、法规赋予监事会的职权， 本着对全体股东负责的精神，认真履行监督职责，现将 2023 年公司监事会工作 汇报如下： 一、本年度监事会工作情况 2023 年度，公司监事会共召开了 7 次会议，具体内容如下： | 会议 | | | 决议 | 会议决议披露 | 会议决议 刊登的信 | | --- | --- | --- | --- | --- | --- | | 届次 | 召开日期 | 会议议案名称 | 情况 | 网站的查询索 | 息披露日 | | | | | | 引 | 期 | | 第五届 | | | | (2023-09)第五 届监事会第十 | | | 监事会 | 2023 年 03 | 《关于公司增加为子公司提供 2023 年度融资担 | 审议 | 八次会议决议 | 2023 年 03 | | 第十八 次会议 | 月 30 日 | 保额度的议案》。 | 通过 | 公告（披露网 站：巨潮资讯 | 月 31 日 | | | | | | 网） | | | | | 1、《关于 ...

Financial Performance - The company's revenue for Q1 2024 was CNY 1,051,117,744.65, a decrease of 11.15% compared to CNY 1,182,959,019.74 in the same period last year[5] - Net profit attributable to shareholders was CNY 4,996,914.97, down 73.92% from CNY 19,158,027.94 year-on-year[5] - Total operating revenue for the current period is ¥1,051,117,744.65, a decrease of 11.1% compared to ¥1,182,959,019.74 in the previous period[23] - Net profit for the current period is ¥5,103,538.76, a decline of 74.0% from ¥19,590,153.69 in the previous period[26] - Operating profit decreased to ¥10,309,517.49, down 54.6% from ¥22,718,679.60 in the previous period[25] - The company reported a total comprehensive income of ¥88,551.05, significantly lower than ¥32,013,079.51 in the previous period[26] Cash Flow - The net cash flow from operating activities was negative CNY 185,951,326.25, a decline of 332.79% compared to a positive CNY 79,880,543.46 in the previous year[14] - Cash flow from operating activities shows a net outflow of ¥185,951,326.25, compared to a net inflow of ¥79,880,543.46 in the previous period[28] - Cash flow from investment activities generated a net inflow of ¥170,091,100.29, recovering from a net outflow of ¥232,850,603.33 in the previous period[28] Assets and Liabilities - Total assets at the end of Q1 2024 were CNY 7,717,611,825.48, a decrease of 3.76% from CNY 8,019,424,770.29 at the end of the previous year[5] - Current assets totaled CNY 4,547,319,044.26, down from CNY 4,816,250,173.52[19] - Total liabilities decreased to CNY 3,122,722,809.34 from CNY 3,415,629,359.52[21] - The company reported a decrease in total non-current assets to CNY 3,170,292,781.22 from CNY 3,203,174,596.77[20] - The total equity decreased slightly to CNY 4,594,889,016.14 from CNY 4,603,795,410.77[22] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 44,937[15] - The company's equity attributable to shareholders reached CNY 4,580,328,960.06, slightly up from CNY 4,579,259,999.09[22] Financial Ratios and Returns - The weighted average return on net assets was 0.11%, down 0.30% from 0.41% in the same period last year[5] - Basic earnings per share decreased to ¥0.01 from ¥0.03 in the previous period, reflecting a 66.7% decline[26] Other Financial Metrics - Financial expenses decreased by 53.01% to CNY 15,524,364.16, primarily due to reduced exchange losses[11] - Investment income increased by 487.80% to CNY 21,805,060.20, compared to a loss of CNY 5,622,688.91 in the previous year[12] - The company experienced a 221.26% increase in other current assets, reaching CNY 284,984,866.80, attributed to an increase in short-term deposits[9] - The company’s financial assets experienced a fair value change loss of ¥8,057,197.02, contrasting with a gain of ¥25,918,162.28 in the previous period[25] - The company’s tax expenses for the current period were ¥5,576,871.35, down from ¥8,283,462.97 in the previous period[25]

奥佳华智能健康科技集团股份有限公司 2023 年度独立董事述职报告 奥佳华智能健康科技集团股份有限公司 2023 年度独立董事述职报告 （独立董事：王志强） 作为奥佳华智能健康科技集团股份有限公司（以下简称"公司"）的独立董 事，本人严格按照《中华人民共和国公司法》、《上市公司独立董事管理办法》、 《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等 相关法律、法规的规定以及《公司章程》、公司《独立董事制度》的有关规定， 在 2023 年的工作中，忠实、勤勉地履行独立董事职务。本人于 2023 年 9 月 4 日起担任公司独立董事，现将本人 2023 年度的履职情况报告如下： 一、基本情况 本人王志强，中国国籍，无境外居留权，男，1967 年出生，博士研究生学 历，厦门大学管理学院教授、博士生导师。现兼任上市公司华厦眼科医院集团股 份有限公司独立董事、厦门厦工机械股份有限公司独立董事，非上市公司厦门华 尔达智能科技股份有限公司董事、厦门金汇峰新型包装材料股份有限公司董事。 2023 年度任期内，本人任职符合《上市公司独立董事管理办法》第六条规 定的独立性要求，不存在影响独立性的情况。 二 ...

奥佳华智能健康科技集团股份有限公司 2023 年度独立董事述职报告 奥佳华智能健康科技集团股份有限公司 2023 年度独立董事述职报告 （独立董事：阳建勋） 作为奥佳华智能健康科技集团股份有限公司（以下简称"公司"）的独立董 事，本人严格按照《中华人民共和国公司法》、《上市公司独立董事管理办法》、 《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等 相关法律、法规的规定以及《公司章程》、公司《独立董事制度》的有关规定， 忠实、勤勉地履行独立董事职务。本人因任期届满于 2023 年 9 月 4 日换届离任， 现将本人 2023 年度任职期间的履职情况报告如下： 一、基本情况 本人阳建勋，中国国籍，无境外居留权，男，1974 年出生，法学博士，厦门 大学法学院教授、硕士生导师。曾任江西共创律师事务所兼职律师、广州仲恒房 屋安全鉴定有限公司法律顾问；曾兼任公司独立董事，现兼任中国银行法学研究 会理事、科华数据股份有限公司独立董事。 2023 年度任期内，本人任职符合《上市公司独立董事管理办法》第六条规定 的独立性要求，不存在影响独立性的情况。 二、2023 年度履职概况 （一）出席公司董事会 ...

证券代码：002614 股票简称：奥佳华 公告编号：2024-07 号 奥佳华智能健康科技集团股份有限公司 2023年度内部控制评价报告 奥佳华智能健康科技集团股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要 求（以下简称企业内部控制规范体系），结合奥佳华智能健康科技集团股份有限 公司（以下简称"公司"）内部控制制度和评价办法，在内部控制日常监督和专 项监督的基础上，我们对公司 2023 年 12 月 31 日（内部控制评价报告基准日） 的内部控制有效性进行了评价。 债券代码：128097 债券简称：奥佳转债 一、重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其 有效性，并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建 立和实施内部控制进行监督。经理层负责组织领导企业内部控制的日常运行。 公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存在任 何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性 承担个别及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及 相关信息 ...

Financial Performance - The company's operating revenue for 2023 was CNY 5,030,460,330.75, a decrease of 16.50% compared to CNY 6,024,336,706.63 in 2022[21]. - The net profit attributable to shareholders for 2023 was CNY 103,203,187.17, representing a slight increase of 1.16% from CNY 102,022,883.31 in 2022[21]. - The net profit after deducting non-recurring gains and losses was CNY 30,774,523.87, down 78.09% from CNY 140,471,252.38 in the previous year[21]. - The net cash flow from operating activities increased by 20.62% to CNY 895,115,094.07, compared to CNY 742,083,023.25 in 2022[21]. - The total assets at the end of 2023 were CNY 8,019,424,770.29, a decrease of 7.91% from CNY 8,707,784,113.72 at the end of 2022[21]. - The net assets attributable to shareholders decreased by 1.68% to CNY 4,579,259,999.09 from CNY 4,657,466,510.02 in 2022[21]. - The basic earnings per share for 2023 were CNY 0.17, an increase of 6.25% from CNY 0.16 in 2022[21]. - The diluted earnings per share decreased by 5.56% to CNY 0.17 from CNY 0.18 in the previous year[21]. - The weighted average return on equity for 2023 was 2.24%, slightly up from 2.16% in 2022[21]. Revenue Breakdown - Total revenue for Q1 2023 was approximately CNY 1.18 billion, with a net profit attributable to shareholders of CNY 19.16 million[25]. - The main business revenue accounted for CNY 4.91 billion, which is 97.62% of total revenue, also down by 16.56% year-on-year[56]. - Revenue from health massage products was CNY 3.70 billion, making up 75.37% of main business revenue, with a decline of 16.61% compared to last year[56]. - The revenue from massage chairs was CNY 2.16 billion, representing 44.04% of main business revenue, down by 13.00% year-on-year[56]. - Domestic sales increased by 19.67% to CNY 1.53 billion, while international sales decreased by 26.58% to CNY 3.39 billion[56]. Market and Product Development - The company's proprietary brand business accounted for 51.46% of total revenue, an increase of 4.00% year-on-year[32]. - Sales of high-end products, such as AI massage robots, saw over 50% growth during the "Double 11" shopping festival in key cities[33]. - The company launched several new models, achieving significant sales in the CNY 10,000 price segment, with OG-7608 TEN+ and X9 ranking first in their respective categories on major e-commerce platforms[33]. - The company has strengthened its market presence in Southeast Asia and along the "Belt and Road" initiative, enhancing its competitive edge in the health massage sector[32]. - The company has successfully launched new affordable massage chairs and small massage appliances to adapt to market demands[35]. Research and Development - The company invested CNY 219 million in R&D during the reporting period, resulting in a total of 1,516 patents obtained[37]. - The flagship massage chair featuring next-generation core technology has entered the trial sales phase, enhancing user experience with precise pressure detection and AI algorithms[39]. - The sixth generation of intelligent core technology has been commercialized, enhancing user experience with features like force detection and closed-loop control[48]. - The company is actively integrating into the Huawei Harmony ecosystem to enhance its smart health living scenarios[48]. Operational Efficiency - The company has streamlined its operations by closing six non-core subsidiaries, focusing on its main business to reduce fixed costs[41]. - The total cost of sales was CNY 3.09 billion, down 22.60% from the previous year, with the main business costs representing 97.47% of total operating costs[64]. - The company’s investment activities resulted in a net cash outflow of CNY 356.27 million, an improvement of 27.39% compared to the previous year[74]. - The company’s cash and cash equivalents decreased by 412.87% to a net decrease of CNY 454.70 million[73]. Governance and Shareholder Engagement - The company held its 2022 annual general meeting on May 18, 2023, with a participation rate of 40.73%, approving several key proposals including the 2022 financial report and profit distribution plan[121]. - The company conducted a temporary shareholders' meeting on August 7, 2023, with a participation rate of 40.77%, where it approved the signing of a management agreement and the election of new board members[121]. - The company plans to apply for a comprehensive credit limit from banks for 2024, as approved in the third temporary shareholders' meeting on November 13, 2023[122]. - The company has revised its governance rules, including the shareholder meeting rules and board meeting rules, to enhance operational efficiency[122]. - The company is committed to improving shareholder value through consistent performance and strategic growth initiatives[128]. Environmental Responsibility - The company is classified as a key pollutant discharge unit according to environmental protection regulations, adhering to various national laws and industry standards[163]. - The total wastewater discharge is 153,000 tons per year, with specific pollutant limits including ammonia nitrogen ≤15 mg/L and chemical oxygen demand ≤100 mg/L[164]. - The company has implemented pollution control facilities, with wastewater treated through a combination of pre-treatment and flotation systems before discharge[165]. - The company has established a self-monitoring plan in compliance with national regulations, with all monitoring data meeting standards during the reporting period[166]. - The company has made regular payments of environmental protection taxes as part of its commitment to environmental governance[168]. Employee and Social Responsibility - The total number of employees at the end of the reporting period was 8,189, with 3,771 in production, 1,216 in sales, and 794 in technical roles[147]. - The company emphasizes employee welfare by providing annual health check-ups and various recreational activities to enhance employee well-being[172]. - The company actively participated in poverty alleviation and rural revitalization projects, collaborating with Gansu's Linxia County for labor cooperation[177]. - The company donated a total of RMB 274,500 in love materials to government and charitable organizations during the reporting period[176]. Risks and Challenges - The company faces risks from macroeconomic fluctuations, which could impact demand for its massage chairs and small appliances[110]. - The company is exposed to exchange rate fluctuations, particularly with its overseas revenue primarily settled in foreign currencies like USD[111]. - The company is vulnerable to raw material and shipping price volatility, which could significantly affect its profitability[112].

奥佳华智能健康科技集团股份有限公司 募集资金存放与使用情况鉴证报告 二O二三年度 关于奥佳华智能健康科技集团股份有限公司有限公司 2023年度募集资金存放与使用情况 专项报告的鉴证报告 信会师报字[2024]第ZA12350号 二、注册会计师的责任 我们的责任是在执行鉴证工作的基础上对募集资金专项报告发 表鉴证结论。 三、工作概述 我们按照《中国注册会计师其他鉴证业务准则第3101号——历史 财务信息审计或审阅以外的鉴证业务》的规定执行了鉴证业务。该准 则要求我们遵守职业道德规范，计划和实施鉴证工作，以对募集资金 专项报告是否在所有重大方面按照中国证券监督管理委员会《上市公 鉴证报告 第 1 页 司监管指引第2号——上市公司募集资金管理和使用的监管要求2022 年修订）》（证监会公告〔2022〕15号）、《深圳证券交易所上市公 司自律监管指引第1号——主板上市公司规范运作》以及《深圳证券 交易所上市公司自律监管指南第2号——公告格式》的相关规定编制， 如实反映奥佳华公司2023年度募集资金存放与使用情况获取合理保 证。在执行鉴证工作过程中，我们实施了包括询问、检查会计记录等 我们认为必要的程序。我们相信，我们 ...

奥佳华智能健康科技集团股份有限公司董事会 董 事 会 2024 年 4 月 26 日 经核查独立董事蔡天智、曹阳、王志强的任职经历以及签署的相关自查性文 件，上述人员未在公司担任除独立董事以外的任何职务，也未在公司主要股东公 司担任任何职务，与公司以及主要股东之间不存在利害关系或其他可能妨碍其进 行独立客观判断的关系，因此，公司独立董事符合《上市公司独立董事管理办法》、 《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等 相关法律法规及《公司章程》中对独立董事独立性的相关要求。 特此公告。 奥佳华智能健康科技集团股份有限公司 关于独立董事独立性自查情况的专项意见 根据中国证券监督管理委员会《上市公司独立董事管理办法》、《深圳证券交 易所股票上市规则》、《深圳证券交易所上市公司自律监管指引第 1 号——主板上 市公司规范运作》等规定，奥佳华智能健康科技集团股份有限公司（以下简称"公 司"）董事会，就公司在任独立董事蔡天智、曹阳、王志强的独立性情况进行评 估并出具如下专项意见： ...

奥佳华智能健康科技集团股份有限公司 2023 年度独立董事述职报告 奥佳华智能健康科技集团股份有限公司 2023 年度独立董事述职报告 （独立董事：薛祖云） 作为奥佳华智能健康科技集团股份有限公司（以下简称"公司"）的独立董 事，本人严格按照《中华人民共和国公司法》、《上市公司独立董事管理办法》、 《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等 相关法律、法规的规定以及《公司章程》、公司《独立董事制度》的有关规定， 忠实、勤勉地履行独立董事职务。本人因任期届满于 2023 年 9 月 4 日换届离任， 现将本人 2023 年度任职期间的履职情况报告如下： 一、基本情况 本人薛祖云，中国国籍，无境外居留权，男，1963 年出生，管理学（会计 学）博士。曾任广州远洋运输公司工程师、中国电子器材厦门公司财务经理、天 健会计师事务所有限公司注册会计师、中青基业投资发展中心财务总监、厦门大 学管理学院会计系教授等；曾兼任公司独立董事，现兼任九牧王股份有限公司、 厦门象屿股份有限公司、福耀玻璃工业集团股份有限公司独立董事。 2023 年度任期内，本人任职符合《上市公司独立董事管理办法》第六条规 ...

奥佳华智能健康科技集团股份有限公司 关联方占用资金情况专项审计说明 二○二三年度 关于奥佳华智能健康科技集团股份有限公司 非经营性资金占用及其他关联资金往来情况 的专项报告 信会师报字[2024]第 12351 号 奥佳华智能健康科技集团股份有限公司全体股东： 我们审计了奥佳华智能健康科技集团股份有限公司(以下简称 "贵公司")2023 年度的财务报表，包括 2023 年 12 月 31 日的合并及 母公司资产负债表、2023 年度合并及母公司利润表、合并及母公司 现金流量表、合并及母公司所有者权益变动表和相关财务报表附注， 并于 2024 年 4 月 25 日出具了报告号为信会师报字[2024]第 ZA12348 号的无保留意见审计报告。 贵公司管理层根据中国证券监督管理委员会《上市公司监管指引 第 8 号——上市公司资金往来、对外担保的监管要求》（证监会公告 〔2022〕26 号）和《深圳证券交易所上市公司自律监管指南第 1 号 ——业务办理》的相关规定编制了后附的 2023 年度非经营性资金占 用及其他关联资金往来情况汇总表（以下简称"汇总表"）。 编制汇总表并确保其真实、准确、完整是贵公司管理层的责任 ...